

**TREATMENT OF MAMMALIAN MYOCARDIUM WITH
MORPHOGEN LOCALLY, OR WITH MORPHOGENICALLY-TREATED
MYOGENIC PRECURSOR CELLS**

Abstract of the Disclosure

The present invention provides methods for the treatment, and pharmaceuticals for use in the treatment, of mammalian subjects at risk of, or afflicted with, loss of or damage to myocardial tissue. The methods involve the administration of certain morphogens, inducers of those morphogens, agonists of the corresponding morphogen receptors, or small molecule morphogenic activators, or implantation of cells induced with those agents. The morphogens useful in the invention include OP1, CBMP-2A (BMP-2), CBMP-2B (BMP-4), and other members of the morphogen family of the TGF β superfamily of growth and differentiation factors.